Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 286-293

  Kim, Hyuncheol ^a   Csaky, Karl G ^b  

^a Sogang University   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Choroidal neovascularization; Integrin antagonist; Intravitreal injection; Nanoparticles

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; IN-VITRO; INTEGRINS; INTRAVITREAL INJECTION; LASER PHOTOCOAGULATION; PEPTIDE SOLUTIONS; SUSTAINED RELEASE; VISION LOSS;

BIODEGRADABLE POLYMERS; DRUG DELIVERY; NANOPARTICLES; OPHTHALMOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

PEPTIDES;

ANGIOGENESIS INHIBITOR; C16Y PEPTIDE; COUMARIN; INTEGRIN ANTAGONIST; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; ENCAPSULATION; HISTOPATHOLOGY; IN VITRO STUDY; LASER COAGULATION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; TOXICITY TESTING;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTEGRINS; LACTIC ACID; MACULAR DEGENERATION; MALE; NANOPARTICLES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RETINA;

EID: 76749087849     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.031     Document Type: Article

References (50)

1. Ferris F.L., Fine S.L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102:1640-1642.
2. Fine S.L., Berger J.W., Maguire M.G., Ho A.C. Age-related macular degeneration. N. Engl. J. Med. 2000, 342:483-492.
3. Bourlais C.L., Acar L., Zia H., Sado P.A., Needham T., Leverge R. Ophthalmic drug delivery systems-recent advances. Prog. Retin. Eye Res. 1998, 17:33-58.
4. Moshfeghi A.A., Peyman G.A. Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 2005, 57:2047-2052.
5. Kim H., Robinson M.R., Lizak M.J., Tansey G., Lutz R.J., Yuan P., et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 2004, 45:2722-2731.
6. Robinson M.R., Lee S.S., Kim H., Kim S., Lutz R.J., Galban C., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 2006, 82:479-487.
7. Slakter J.S., Bochow T.W., D'Amico D.J., Marks B., Jerdan J., Sullivan E.K., et al. Anecortave acetate (15milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006, 113:3-13.
8. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444.
9. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816. VEGF inhibition study in ocular neovascularization clinical trial group.
10. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
11. Lim J.I., Wolitz R.A., Dowling A.H., Bloom H.R., Irvine A.R., Schwartz D.M. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 1999, 127:288-293.
12. Shane T.S., Martin D.F. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 2003, 136:649-654.
13. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J. Control. Release 2009, 136:2-13.
14. Hironaka K., Inokuchi Y., Tozuka Y., Shimazawa M., Hara H., Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J. Control. Release 2009, 136:247-253.
15. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
16. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 1996, 93:9764-9769.
17. Kamizuru H., Kimura H., Yasukawa T., Tabata Y., Honda Y., Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci. 2001, 42:2664-2672.
18. Umeda N., Kachi S., Akiyama H., Zahn G., Vossmeyer D., Stragies R., et al. Suppression and regression of choroidal neovascularization by systemic administration of an {alpha}5{beta}1 integrin antagonist. Mol. Pharmacol. 2006, 69:1820-1828.
19. Ponce M.L., Kleinman H.K. Identification of redundant angiogenic sites in laminin alpha1 and gamma1 chains. Exp. Cell Res. 2003, 285:189-195.
20. Coombes A.G., Yeh M.K., Lavelle E.C., Davis S.S. The control of protein release from poly(dl-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J. Control. Release 1998, 52:311-320.
21. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 2003, 20:212-220.
22. Lee W.K., Park J.Y., Jung S., Yang C.W., Kim W.U., Kim H.Y., et al. Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J. Control. Release 2005, 105:77-88.
23. Edelman J.L., Castro M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 2000, 71:523-533.
24. Semkova I., Peters S., Welsandt G., Janicki H., Jordan J., Schraermeyer U. Investigation of laser-induced choroidal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci. 2003, 44:5349-5354.
25. Martinez-Sancho C., Herrero-Vanrell R., Negro S. Poly (d,l-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J. Microencapsul 2003, 20:799-810.
26. de Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.C., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 2004, 34:3702-3712.
27. He Y., Wang J.C., Liu Y.L., Ma Z.Z., Zhu X.A., Zhang Q. Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. J. Ocular Pharmacol. Ther. 2006, 22:121-131.
28. Jackson T.L., Antcliff R.J., Hillenkamp J., Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest. Ophthalmol. Vis. Sci. 2003, 44:2141-2146.
29. Mordenti J., Cuthbertson R.A., Ferrara N., Thomsen K., Berleau L., Licko V., et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 1999, 27:536-544.
30. Durairaj C., Shah J.C., Senapati S., Kompella U.B. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm. Res. 2009, 26:1236-1260.
31. Fialho S.L., da Silva Cunha A. Manufacturing techniques of biodegradable implants intended for intraocular application. Drug Deliv. 2005, 12:109-116.
32. Morita Y., Ohtori A., Kimura M., Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(dl-lactic acid) implants. Biol. Pharm. Bull. 1998, 21:188-190.
33. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. 1991, 32:1785-1790.
34. Bourges J.L., Gautier S.E., Delie F., Bejjani R.A., Jeanny J.C., Gurny R., et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 2003, 44:3562-3569.
35. Solheim E., Sudmann B., Bang G., Sudmann E. Biocompatibility and effect on osteogenesis of poly(ortho ester) compared to poly(dl-lactic acid). J. Biomed. Mater. Res. 2000, 49:257-263.
36. Grayson A.C., Voskerician G., Lynn A., Anderson J.M., Cima M.J., Langer R. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J. Biomater. Sci. Polym. Ed. 2004, 15:1281-1304.
37. Sakurai E., Ozeki H., Kunou N., Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001, 33:31-36.
38. Pannicke T., Uckermann O., Iandiev I., Wiedemann P., Reichenbach A., Bringmann A. Ocular inflammation alters swelling and membrane characteristics of rat Muller glial cells. J. Neuroimmunol. 2005, 161:145-154.
39. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
40. Gref R., Couvreur P., Barratt G., Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003, 24:4529-4537.
41. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini-Rev. Med. Chem. 2006, 6:227-234.
42. Yasuda M., Ohbayashi M., Ohhinata K., Yamamoto T. The involvement of integrin alphavbeta3 in polymorphonuclear leukocyte-induced angiogenesis in bovine aortic endothelial cells. Life Sci. 2004, 75:421-434.
43. Kerr J.S., Mousa S.A., Slee A.M. Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 2001, 14:143-150.
44. Speicher M.A., Danis R.P., Criswell M., Pratt L. Pharmacologic therapy for diabetic retinopathy. Expert Opin. Emerg. Drugs 2003, 8:239-250.
45. Capello A., Krenning E.P., Bernard B.F., Breeman W.A., Erion J.L., de Jong M. Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med. 2006, 47:122-129.
46. Yasukawa T., Hoffmann S., Eichler W., Friedrichs U., Wang Y.S., Wiedemann P. Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist. Curr. Eye Res. 2004, 28:359-366.
47. Kim H., Robinson S.B., Csaky K.G. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 2009, 26:329-337.
48. Nishihara H. Studies on the ultrastructure of the inner limiting membrane of the retina-distribution of anionic sites in the inner limiting membrane of the retina. Nippon Ganka Gakkai Zasshi 1991, 95:951-958.
49. Bunt-Milam A.H., Saari J.C., Klock I.B., Garwin G.G. Zonulae adherentes pore size in the external limiting membrane of the rabbit retina. Invest. Ophthalmol. Vis. Sci. 1985, 26:1377-1380.
50. Bejjani R.A., BenEzra D., Cohen H., Rieger J., Andrieu C., Jeanny J.C., et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 2005, 11:124-132.